Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease e...
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
About this item
Full title
Author / Creator
Hiraoka, Atsushi , Kumada, Takashi , Tada, Toshifumi , Tani, Joji , Kariyama, Kazuya , Fukunishi, Shinya , Atsukawa, Masanori , Hirooka, Masashi , Tsuji, Kunihiko , Ishikawa, Toru , Takaguchi, Koichi , Itobayashi, Ei , Tajiri, Kazuto , Shimada, Noritomo , Shibata, Hiroshi , Ochi, Hironori , Kawata, Kazuhito , Yasuda, Satoshi , Toyoda, Hidenori , Aoki, Tomoko , Tanaka, Takaaki , Ohama, Hideko , Nouso, Kazuhiro , Tsutsui, Akemi , Nagano, Takuya , Itokawa, Norio , Arai, Taeang , Okubo, Tomomi , Imai, Michitaka , Koizumi, Yohei , Nakamura, Shinichiro , Joko, Koji , Hiasa, Yoichi , Kudo, Masatoshi , The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) and Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
It was recently reported that hepatocellular carcinoma (HCC) patients with non-alcoholic steatohepatitis (NASH) are not responsive to immune-checkpoint inhibitor (ICI) treatment. The present study aimed to evaluate the therapeutic efficacy of lenvatinib in patients with non-alcoholic fatty liver disease (NAFLD)/NASH-related unresectable-HCC (u-HCC)...
Alternative Titles
Full title
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
Authors, Artists and Contributors
Author / Creator
Kumada, Takashi
Tada, Toshifumi
Tani, Joji
Kariyama, Kazuya
Fukunishi, Shinya
Atsukawa, Masanori
Hirooka, Masashi
Tsuji, Kunihiko
Ishikawa, Toru
Takaguchi, Koichi
Itobayashi, Ei
Tajiri, Kazuto
Shimada, Noritomo
Shibata, Hiroshi
Ochi, Hironori
Kawata, Kazuhito
Yasuda, Satoshi
Toyoda, Hidenori
Aoki, Tomoko
Tanaka, Takaaki
Ohama, Hideko
Nouso, Kazuhiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Arai, Taeang
Okubo, Tomomi
Imai, Michitaka
Koizumi, Yohei
Nakamura, Shinichiro
Joko, Koji
Hiasa, Yoichi
Kudo, Masatoshi
The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_1c086d02fb67435ca602adcb170580af
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1c086d02fb67435ca602adcb170580af
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-021-96089-x
